Amidst Adversity: Scientific Breakthroughs of 2025

Aaron Schwartz/Sipa USA via Reuters Connect

In 2025, science faces numerous challenges, ranging from vaccine skepticism within the U.S. government to the ongoing global inertia in addressing climate change. Those who value logic and empirical evidence must rally against this growing adversity. New Scientist not only highlights these issues but also celebrates the awe and curiosity elicited by space exploration.

As you prepare to indulge in the joyful festivities represented in our Double Vacation issue, it’s essential to recognize the threats encountered by those passionate about science. The past year has been riddled with stark instances of scientific principles being distorted and misapplied.

The degradation of U.S. scientific integrity under President Donald Trump is glaring, even for those outside the country (see “Donald Trump and Elon Musk jeopardize science in 2025”). For many years, the U.S. has been a significant funder of scientific research, benefiting both the nation and many others. However, that narrative shifted dramatically this year. By severely cutting funding (or, in Elon Musk’s case, going as far as using a chainsaw), numerous breakthroughs will remain undiscovered, essential medicines will go untested, and technological advancements will stagnate, ultimately impoverishing us.

While government funding is crucial, it’s not the sole source. Two articles this year underscore the risks inherent in relying on corporate interests for scientific funding. If you are a regular reader of New Scientist, you may have encountered Colossal Biosciences, a U.S. company that claims to work on “de-extinction” of endangered species (see “De-extinction of endangered species captivated 2025, yet fell short of expectations”). One of their most talked-about acts this year was the introduction of genetically modified gray wolves named Romulus, Remus, and Khaleesi.


Results may take time, but science exists to serve, save, and delight us all.

Colossal asserted that these were the first extant dire wolves since their extinction 10,000 years ago—a claim fervently endorsed by global media despite backlash from independent scientists. In the ongoing struggle between fact and spectacle, it seems the latter continues to prevail.

A similar scenario unfolded in a British documentary that aired in November, entitled Hitler’s DNA: The Dictator’s Blueprint. Although the scientists succeeded in identifying and sequencing the genome of the infamous dictator, the sensationalistic interpretations asserting potential schizophrenia or autism cast doubt on the credibility of their findings. While the documentary and its distressing headlines have faded, the scientific paper that would allow us to critically assess the study’s conclusions is still forthcoming.

On another front, progress in climate action is evident. Science and public policy have been effectively aligned since the Paris Agreement, which was designed to limit global warming to below 1.5°C. Unfortunately, it appears this goal is not being realized.

The Paris Agreement includes a “ratchet” mechanism aimed at holding nations accountable for making new commitments every five years to combat climate change. Regrettably, about 95% of countries failed to meet their deadlines by February, with only around 60% making progress before the COP30 climate summit in Belem, Brazil, in November.

The retreat didn’t stop there. As we approached the end of 2024, we urged Brazilian President Luiz Inacio Lula da Silva to “take the stage with solemn world leaders who have concrete plans to improve and publicly recognize the failures of the COP process thus far.” Yet, countries could not even reach a consensus on the inclusion of “fossil fuels” in the final COP30 document.

But let’s shift focus from the gloom for a moment. After all, it’s a festive time, and there’s much to celebrate! Another significant theme of 2025 is the centennial of quantum mechanics, extensively covered in our special issue in April. The year concludes with the exciting revelation that a thought experiment conceived by Einstein and Bohr has come to fruition (see “Quantum experiment resolves century-long tension between Einstein and Bohr”). This certainly confirms the strangeness of quantum mechanics!

Other delightful news in 2025 includes the ongoing success of GLP-1 medications not only aiding weight loss but also treating a myriad of conditions (see “The transformative potential of GLP-1 drugs skyrocketed in 2025”) and, in perhaps a playful twist, individuals being able to perceive entirely new colors (see “New colors witnessed by people for the first time in 2025”).

This issue offers an enticing array of content to please both your palate and your intellect during the holiday season. If you’re in the mood for a fresh take on Charles Dickens, explore “How Three Imaginary Physics Demons Tear the Laws of Nature Apart,” which tells the tale of three demons haunting a physicist. As you unwind after another frenetic year, consider a novel approach to meditation for those with limited time (see “Too Busy to Meditate? Microdosing Mindfulness Packs Major Health Benefits”). Learn about the top careers in science at the Touch and Tickle lab, with insights on “What the Evolution of Tickling Reveals About Being Human.” Finally, why not quench your thirst with the world’s oldest beer (see: “Did ancient peoples begin farming to increase their beer consumption?”)?

As we set our sights on 2026 and the challenges that lie ahead, let’s not forget the immense power and wonder that science holds. Despite skepticism and negativity, scientific research and the knowledge it imparts remain unrivaled in understanding and improving our world. Though it may take time to witness results—much like the century-spanning gap between Einstein and Bohr’s debate and its resolution—science exists to serve, save, and bring joy to us all.

Here’s to hoping for better fortune in the coming year, or at the very least, a more advantageous outcome from random chance.

Source: www.newscientist.com

Unraveling the Lasting Impact of Childhood Adversity

SEI 270359063

Childhood hardships can have lasting impacts

Ton Photography/Getty Images

Individuals facing significant adversity in their early years show elevated levels of specific proteins in their brains, a discovery that may shed light on the connection between childhood difficulties and persistent mental health issues. Moreover, medications targeting this protein could potentially mitigate these effects in the future.

About 1 in 5 adolescents in the U.S. report having experienced at least four potentially traumatic events, such as abuse, neglect, homelessness, or losing a parent. Studies indicate that these experiences can hinder brain development, leading to an increased risk of mental health conditions, including depression, persisting into adulthood.

“The mechanisms through which early life stress and adversity exert lasting effects are still not fully understood,” states Christoph Anacker from Columbia University, New York. “Individuals who have endured childhood trauma usually exhibit lesser responsiveness to current antidepressant treatments.”

Prior studies have indicated that individuals with depression show elevated symptoms such as heightened levels of the protein SGK1 (serum and blood glucocorticoid-regulated kinase 1). While little is known about this protein’s exact role, it seems to affect brain cell processing and information dissemination .

To investigate its effects further, Anacker and colleagues examined SGK1 levels in the postmortem brains of 50 men, 36 of whom had died by suicide. Each participant had completed a questionnaire detailing experiences of physical or sexual abuse before the age of 16.

The research revealed that in the hippocampus—a brain region linked to memory and stress—the levels of genetic material for SGK1 were approximately 33 percent higher in men who had died by suicide compared to those who had not, with even higher levels in those who faced childhood adversity.

In another segment of the study, over 8,500 children aged 9-10 were analyzed, revealing that those diagnosed with depression were more likely to exhibit heightened activity of the SGK1-encoding gene, which was also connected to instances of childhood adversity.

Finally, the researchers conducted an experiment injecting 10 adult male mice daily for 10 days with a novel drug designed to inhibit SGK1. After each injection, the mice were placed in a cage with aggressive counterparts for 5 minutes to elevate stress levels.

At the conclusion of the 10-day study, the treated mice exhibited fewer signs of anxiety and depression than a control group that received saline injections. Notably, the treated group spent more than double the time in the center of a vacant cage rather than cowering in a corner, compared to the control subjects.

“Lowering SGK1 levels in the hippocampus enhances resilience to stress in mice,” states Anacker. A similar biological pathway appears to exist in humans, suggesting that targeting SGK1 may alleviate depression in those who faced early hardships. Although the exact mechanism by which SGK1 contributes to mental health issues remains unclear, one theory is that it inhibits the formation of brain cells in the hippocampus.

While the drug utilized in this study is not yet approved for human use, other SGK1 inhibitors are undergoing clinical trials for specific heart conditions. If proven safe, these could potentially be repurposed for treating mental health disorders, according to Anacker. However, “this fundamental research in rodents is still far from providing the conclusive evidence needed to identify practical drug targets for humans,” notes Katie McLoughlin at Harvard University.

If you need someone to talk to, reach out to the British Samaritans at 116123; the U.S. National Suicide Prevention Lifeline at 1-800-273-8255; or find hotlines in other countries.

Topic:

Source: www.newscientist.com